Skip to main content

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

Receive weekly updates on the oncology news that matters

Read the transcript

Read more about the STAMPEDE updates here

Back to the WCLC 2019 conference hub

Related topics